| |
Learn how Transmission Electron Microscopy (TEM) enables precise quantification of virus-like particles (VLPs) in unprocessed bulk material. Discover the importance of TEM in viral safety testing and cell line characterization. Check out our scientific poster!
|
|
Today’s Big NewsOct 24, 2024 |
|
Wednesday, October 29, 2024 | 11am ET / 8am PT Real-world data is essential to gaining insights into a patient’s diagnostic journey. However, many pharma companies may not be using lab data to its full potential. Join us to discuss how today’s robust lab data sources can help improve patient access and time to treatment, leading to better patient outcomes. Register now.
|
|
| By Darren Incorvaia Between the two companies, more than 560 people joined trials without being told they had a heightened risk of dangerous side effects such as brain bleeding or swelling, The New York Times reported. |
|
|
|
By Zoey Becker The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a cost-cutting scramble as it moves to explore "strategic alternatives." |
By Zoey Becker The CDC's immunization committee voted to expand its usage recommendation for pneumococcal conjugate vaccines, a class that includes both Pfizer’s Prevnar 20 and Merck’s Capvaxive. |
By Conor Hale After receiving a green light earlier this year from FDA, Medtronic has now collected a European approval for the latest version of its TAVR implant. |
By Kevin Dunleavy Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. It licensed ALXN-1840, a candidate for the treatment of Wilson disease that was previously considered promising enough that Alexion, now an AZ subsidiary, paid $855 million to acquire it six years ago. |
By Angus Liu In a new deal potentially worth more than $1 billion, Roche is paying Dyno $50 million upfront to design novel adeno-associated virus vectors as delivery tools for gene therapies against neurological diseases. |
By Kevin Dunleavy Preliminary results from two trials showed that GSK’s RSV vaccine Arexvy has potential in a broad age range of immunocompromised and other at-risk individuals, potentially positioning the shot for a larger population. |
By Andrea Park The CDC seems to be taking an “if it ain’t broke” approach to its annual flu vaccine push. Rather than debuting an entirely new concept, this year’s campaign is instead a revamped version of last year’s “Wild to Mild” initiative. |
By Darren Incorvaia Poseida Therapeutics’ gene therapy for hereditary angioedema reduced kallikrein protein activity in a mouse model of the disease and edited a gene in the livers of nonhuman primates, the company said in an Oct. 24 release. |
By Nick Paul Taylor Moderna has identified a fundamental barrier to vaccination: many people don’t know they’re eligible. The biotech found almost one-third of people with underlying health conditions in the U.K. are unaware they could get vaccinated—and has kicked off an awareness drive to get the message out. |
By Fraiser Kansteiner In the phase 1/1b ARC-20 study of Arcus’ candidate casdatifan in metastatic clear cell renal cell carcinoma, the biotech’s HIF-2a inhibitor achieved a confirmed overall response rate (ORR) of 25%. Analysts at Evercore ISI were optimistic about Arcus’ data and the candidate's prospects against an approved rival. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcastsDon’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| eBookNeed the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
